COMPANY ANNOUNCEMENT
Invitrocue Pte Ltd (IVQ-SG)

Singapore's Ministry of Health Grant License Approval For Commercial use for Onco-PDO™ - Personalized Cancer Drug Screening

Summary

- **Invitrocue Singapore received approval by Singapore Ministry of Health (MOH) under the Healthcare Services Act (HCSA) for the commercial use of Onco-PDO™.**
- **IVQ's Onco-PDO™ patented and proprietary cancer drug screening service offers insights of patients' own tumour response to most chemotherapeutic and targeted drugs, to better help inform physicians in their therapy regime and drug selection.**
- **Onco-PDO™ is a personalised, fast and highly accurate laboratory service in screening solid tumour cancers for resistance or sensitivity against a broad range of cancer drugs.**
- **Onco-PDO™ is currently CE Marked and approved for commercial use in EU, Germany, Hong Kong and South America.**

13 July 2023: Leading Life Sciences company **Invitrocue Singapore, a wholly owned subsidiary company of Invitrocue Ltd (IVQ) ('Invitrocue' or 'the Company'),** is pleased to announce the approval of its Onco-PDO personalized cancer screening service for commercial use by the Singapore Ministry of Health (MOH), under the Healthcare Services Act (HCSA).

Onco-PDO™

Onco-PDO™ utilizes advanced and proprietary approaches to regrow patients' own cancer tissue in its laboratories that mimic accurately those same tumors in the patient's body. Copies of the cancer avatar are then generated for testing against cancer drugs like chemotherapeutics or targeted drugs in its laboratories to quantify the selected cancer drugs' ability to kill the patient's tumor and the corresponding subclasses of cancer cells. The Onco-PDO™ reports offer insights on possible cancer drugs' resistance and sensitivity when used clinically by qualified physicians in their treatment regime and drug selection.

Based on IVQ's global data, the company can form these human heterogenous cancer organoids 92% of the time successfully in its laboratories, and more critically IVQ have demonstrated a consistent laboratory to clinical response correlation rate of more than 80% accuracy.

Onco-PDO™ have been in development and validation by IVQ since 2015 through its laboratories in Singapore, Germany and Hong Kong. The company's Onco-PDO™ 3D cancer organoids accurately captures the heterogeneity of patients' cancer and the subpopulations of cancer cells with distinct genotypes and phenotypes, which exhibit diverse biological behaviours. These organoids faithfully replicate not only

Invitrocue Pte Ltd | ACRA 201224616W | www.invitrocue.com
51, Science Park Road, #01-11/13, Aries, Science Park 2, Singapore 117586

characteristics of the primary tumour and metastatic sites but also exhibit a wide range of responses to drug treatments. This approach have since been used extensively in numerous human clinical trials and studies. Onco-PDO™ received CE Mark registration for use in European Union in 2018 and approval for use in Hong Kong in 2020. Supported by extensive scientific publications and strong clinical validations, IVQ is working towards having Onco-PDO™ being recognised as part of the global standard for Cancer Treatment Guidelines in drug selection.

Onco-PDO™ is currently validated for use against most solid tumour cancers, including across more than 130 different chemotherapeutic compounds and targeted drugs.

TURNAROUND TIME

Depending on cancer type and complexity (single identifiable primary tumour or metastasis sites), IVQ will generate a detailed drug response report on an average of 14 days from receiving the tissue sample at its laboratories. This rapid turnaround time enables the test results to be made available to physicians in a clinically relevant timeframe.

FUTURE DEVELOPMENTS

IVQ is currently conducting studies on integrating its proprietary in-vitro cancer platform with another of its patented in-vivo platform designed to offer similar personalised screening for Immunotherapy treatment.

For further information and inquiry, please contact:

Ms. Susan Chia
General Manager, Singapore
M: +65 6460 0497
E: susan.chia@invitrocue.com

www.invitrocue.com

About Invitrocue (IVQ)

Invitrocue Limited (VQ) is an innovative life sciences company commercializing products and services in Oncology and Pharmacology, based on ground-breaking 3D models and Humanized mice platform. The company also offers an invivo platform for pharmacology services.

Headquartered in Singapore and with operations in Australia, China, Hong Kong and Germany, Invitrocue's in-vitro Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support personalized clinical decisions. In addition, Invitrocue's HiMice novel technology allows for the in-vivo testing of drugs and vaccines using a stable and fully human immune response.

To learn more, please visit: www.invitrocue.com